

REMARKS

As noted above, applicants hereby elect Group II, claims 2, 7, 8, and 12-14, for examination at this time. With the above amendment, claims 2, 7, 8, and 12 are canceled, claims 13 and 14 are amended and new claims 20-23 are added. Accordingly, claims 13-14 and 20-23 are currently under consideration. Applicants urge that no new matter is added by this amendment and that support for the new claims can be found throughout the specification as filed. In particular, support for 90% identity can be found, for example, on page 28, lines 12 – 16. Support for adjuvants can be found, for example, on page 86, line 26 – page 90, line 2. Support for inducing an immune response and for Th1-type response can be found, for example, on page 87, lines 14 – 25. Support for stimulation of T cells can be found throughout the application as filed, in particular on page 78, line 1 – page 79, line 18. It should be noted that the above amendments are made without prejudice to prosecution of any subject matter modified and/or removed by this amendment in a related divisional, continuation and/or continuation-in-part application.


The Commissioner is authorized to charge any additional fees due by way of this Amendment, or credit any overpayment, to our Deposit Account No. 19-1090.

Consideration of the claims is now requested.

Respectfully submitted,

Tongtong Wang et al.

Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:kcy
Enclosure:
Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031